HTORR High Priority Alzheimer's Disease and Related Dementias Human Biospecimen Resource

HTORR 高优先级阿尔茨海默氏病和相关痴呆症人类生物样本资源

• 批准号: 10489968
• 负责人: Thomas J Bell
• 金额: $ 32.14万
• 依托单位: NATIONAL DISEASE RESEARCH INTERCHANGE
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-17 至 2022-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10489968
• 关键词: Address; Administrative Supplement; Affect; Age; Alzheimer' s Disease; Alzheimer' s disease related dementia; Alzheimer' s disease risk; American; Area; Autopsy; Award; Awareness; Biological Models; Biomedical Research; Blood; Brain; Caregivers; Case Study; Cerebrovascular Disorders; Collaborations; Collection; Communication; Communities; Complement; Complex; Custom; Data; Dementia; Development; Diabetes Mellitus; Diagnosis; Disease; Eligibility Determination; Etiology; Exhibits; Experimental Designs; Experimental Models; Feedback; Functional disorder; Funding; Geography; Goals; Grant; Health Services Accessibility; Healthcare Systems; Human; Human Activities; Hypertension; Investigation; Liquid substance; Methodology; Methods; Modeling; National Institute on Aging; Neurodegenerative Disorders; Neurologic; Obesity; Organ; Organ Procurements; Parents; Pathogenesis; Pathology; Patients; Play; Principal Investigator; Procedures; Protocols documentation; Provider; Race; Recommendation; Recording of previous events; Recovery; Reproducibility; Research; Research Personnel; Research Priority; Resources; Sampling; Scientific Advances and Accomplishments; Scientist; Services; Site; Source; Standardization; Tissue Banks; Tissue Sample; Tissues; Training; United States National Institutes of Health; Universities; biobank; body system; cohort; diagnostic strategy; effective therapy; experimental analysis; human tissue; improved; interest; invention; nervous system disorder; neuropathology; outreach; preservation; programs; recruit; screening; sex; success; symposium; tissue resource; translational study; treatment strategy; web site

Program Director/Principal Investigator (Last, First, Middle): Bell, Thomas, J. Project Summary: The development of effective treatments or cures for a wide range of diseases requires translational studies that are directly relevant to human pathophysiology. The use of human biospecimens plays a key role in accelerating scientific discoveries in neurological research by providing scientists with a direct experimental model system to advance understanding of pathogenesis and treatment of neurological disease, including Alzheimer’s disease and related dementias (AD/ADRD). To address several complex issues facing AD/ADRD research, including disease etiology as well as the development of improved diagnostics and treatment strategies, investigators require access to a unique human tissue resource that could provide rigorous and uniform collection of human biospecimens from defined cohorts of post mortem AD/ADRD and normal control donors to yield consistent and reproducible experimental results for inventive and groundbreaking studies. As a leading human tissue provider for the biomedical research community, the National Disease Research Interchange (NDRI) is a 501(c)(3), not- for-profit organization that remains at the forefront of coordinating biospecimen procurement to match the needs of advancing scientific experimental methodologies, enabling cutting-edge research. For over 30 years, NDRI has received NIH funding for the parent award to this administrative supplement, the Human Tissue and Organs for Research Resource (HTORR) Grant Number: U420DO11158. To address the high priority areas of research for AD/ADRD that require both post mortem biospecimen collection that are beyond the scope of HTORR, NDRI is expanding their capabilities to create a new resource, the AD/ADRD Human Biospecimen Resource (ADBR), funded by the active award 3U42OD011158-30S1. In Program Year 3 of the ADBR, NDRI continued to follow the recommendations from ADBR Advisory Council regarding biospecimen collection and distribution for the ADBR that align with an unmet or under represented need in the field. For the current proposal to continue the progression of the ADBR, NDRI proposes to enhance the success of ADBR’s service to investigators in PY4 by 1) providing a nationwide network of TSS to provide access to diverse post mortem diseased and non-diseased donor cohorts, 2) recovering and distributing CNS tissues in addition to other tissues and fluids of interest, and 3) enhancing communication to the biomedical research community to recruit new ADBR investigators and assess unmet needs of the AD/ADRD field. In contrast to similar resources, the ADBR’s extensive outreach efforts and customized approach to investigator needs are key differentiators for the resource. Collectively, the ADBR’s goals and efforts provides a dynamic and synergistic NIH-funded resource to support the advancement of critical unmet research needs for the AD/ADRD research community. Relevance: As the most common cause of dementia, AD is a devastating, progressive neurodegenerative disease that affects over 5.7 million Americans (Alzheimer’s Association et al, 2018) and has a significant burden on the US healthcare system as well as caregivers. As of yet, there are no disease-modifying treatment options available for AD/ADRD patients, making this a high priority for the research community. The objective of this proposal is to provide biospecimens from post mortem AD/ADRD donors, as well as non- diseased control donors for the AD/ADRD Human Biospecimen Resource (ADBR) that are suitable to support critical lines of investigation that address high priority needs and key issues in the field. OMB No. 0925-0001/0002 (Rev. 03/2020 Approved Through 02/28/2023) Page Continuation Format Page

项目主任/首席调查员(最后、第一、中间)：Bell，Thomas，J. 项目总结： 开发有效的治疗方法或治疗范围广泛的疾病需要转化性研究， 与人类的病理生理学直接相关。人类生物有机体的使用在加速发展方面起着关键作用 通过为科学家提供直接的实验模型系统来实现神经学研究中的科学发现 进一步了解包括阿尔茨海默病在内的神经系统疾病的发病机制和治疗 和相关痴呆症(AD/ADRD)。为了解决AD/ADRD研究面临的几个复杂问题，包括 疾病病因学以及改进的诊断和治疗策略的发展，调查人员 需要访问独特的人体组织资源，以提供严格和统一的人类组织集合 来自死后AD/ADRD和正常对照捐赠者的确定队列的生物谱，以产生一致的和 发明性和开创性研究的可重复性实验结果。作为领先的人体组织供应商 对于生物医学研究界来说，国家疾病研究交换(NDRI)是501(C)(3)，而不是- 在协调生物素采购以满足需求方面保持领先地位的营利性组织 推进科学实验方法，使尖端研究成为可能。30多年来，NDRI 已经收到了NIH为这一行政副刊，人体组织和器官的父母奖提供的资金 研究资源(HTORR)资助编号：U420DO11158。解决高度优先的研究领域 对于AD/ADRD，要求进行超出HTORR范围的死后生物标本收集，NDRI 正在扩大他们的能力，以创建一种新的资源，AD/ADRD人类生物标本资源(ADBR)， 由现行奖项3U42OD011158-30S1资助。在ADBR的方案第3年，NDRI继续遵循 ADBR咨询委员会关于生物检疫菌剂收集和分配的建议 ADBR符合现场未得到满足或未得到充分代表的需求。对于当前的提案，以继续 关于ADBR的进展，NDRI建议通过以下方式加强ADBR在第四财年向调查人员提供服务的成功 1)提供全国范围内的TSS网络，以提供各种不同的死后疾病和非疾病的信息 捐赠者队列，2)恢复和分发CNS组织以及其他感兴趣的组织和液体，以及 3)加强与生物医学研究界的沟通，以招募新的ADBR研究人员和 评估AD/ADRD领域未满足的需求。与类似的资源形成对比的是，ADBR的广泛宣传 针对调查员需求的努力和定制方法是该资源的关键区别因素。 总体而言，ADBR的目标和努力为NIH提供了一个动态和协同的资金来源，以 支持推进AD/ADRD研究界尚未满足的关键研究需求。 相关性：作为痴呆症最常见的原因，阿尔茨海默病是一种毁灭性的进行性神经退行性疾病 影响超过570万美国人的疾病(阿尔茨海默氏症协会等人，2018年)，并具有显著的 给美国医疗系统和照顾者带来了负担。到目前为止，还没有改变疾病的方法 为AD/ADRD患者提供治疗选择，使其成为研究界的高度优先事项。这个 这项提议的目标是提供死后AD/ADRD捐赠者的生物检疫，以及非 AD/ADRD人类生物样品资源(ADBR)适宜支持的疾病对照供体 解决高优先级需求和外地关键问题的关键调查路线。 OMB编号0925-0001/0002(批准的第03/2020版至2023年2月28日)续页格式页